Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease

Neurobiology of Disease

Volumn 82, Issue , 2015, Pages 466-477

  Ma, Qian ^a   Yang, Jianmin ^a   Li, Thomas ^a   Milner, Teresa A ^b,c   Hempstead, Barbara L ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Cortex; Huntington's disease; Mature BDNF; Myelin; Oligodendrocyte; P75NTR; ProBDNF; Sortilin; Striatum; ZQ175 mice

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIN RECEPTOR P75; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; ISOPROTEIN; NERVE GROWTH FACTOR RECEPTOR; SORTILIN; TNFRSF16 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN NERVE CELL; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; HUNTINGTON CHOREA; IMMUNOREACTIVITY; MALE; MOUSE; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSORIMOTOR CORTEX; SIGNAL TRANSDUCTION; UPREGULATION; AGING; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENE TARGETING; HIPPOCAMPUS; METABOLISM; MYELIN SHEATH; PATHOLOGY; TRANSGENIC MOUSE; ULTRASTRUCTURE;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; AGING; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; GENE KNOCK-IN TECHNIQUES; HIPPOCAMPUS; HUNTINGTON DISEASE; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELIN SHEATH; OLIGODENDROGLIA; PROTEIN ISOFORMS; RECEPTOR, TRKB; RECEPTORS, NERVE GROWTH FACTOR; SENSORIMOTOR CORTEX;

EID: 84940209789     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.08.008     Document Type: Article

References (60)

1. Altar C.A., Cai N., Bliven T., Juhasz M., Conner J.M., Acheson A.L., Lindsay R.M., Wiegand S.J. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997, 389:856-860.
2. Anastasia A., Deinhardt K., Chao M.V., Will N.E., Irmady K., Lee F.S., Hempstead B.L., Bracken C. Val66Met polymorphism of BDNF alters prodomain structure to induce neuronal growth cone retraction. Nat. Commun. 2013, 4:2490.
3. Baquet Z.C., Gorski J.A., Jones K.R. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J. Neurosci. 2004, 24:4250-4258.
4. Bartzokis G., Lu P.H., Tishler T.A., Fong S.M., Oluwadara B., Finn J.P., Huang D., Bordelon Y., Mintz J., Perlman S. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem. Res. 2007, 32:1655-1664.
5. Beattie M.S., Harrington A.W., Lee R., Kim J.Y., Boyce S.L., Longo F.M., Bresnahan J.C., Hempstead B.L., Yoon S.O. ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury. Neuron 2002, 36:375-386.
6. Bemelmans A.P., Horellou P., Pradier L., Brunet I., Colin P., Mallet J. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum. Gene Ther. 1999, 10:2987-2997.
7. Bobrowska A., Paganetti P., Matthias P., Bates G.P. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease. PLoS ONE 2011, 6.
8. Bourikas D., Mir A., Walmsley A.R. LINGO-1-mediated inhibition of oligodendrocyte differentiation does not require the leucine-rich repeats and is reversed by p75(NTR) antagonists. Mol. Cell. Neurosci. 2010, 45:363-369.
9. Brito V., Puigdellivol M., Giralt A., del Toro D., Alberch J., Gines S. Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies. Cell Death Dis. 2013, 4.
10. Canals J.M., Pineda J.R., Torres-Peraza J.F., Bosch M., Martin-Ibanez R., Munoz M.T., Mengod G., Ernfors P., Alberch J. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 2004, 24:7727-7739.
11. Casaccia-Bonnefil P., Carter B.D., Dobrowsky R.T., Chao M.V. Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. Nature 1996, 383:716-719.
12. Cattaneo E., Zuccato C., Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 2005, 6:919-930.
13. Chang A., Nishiyama A., Peterson J., Prineas J., Trapp B.D. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J. Neurosci. 2000, 20:6404-6412.
14. Charalampopoulos I., Vicario A., Pediaditakis I., Gravanis A., Simi A., Ibanez C.F. Genetic dissection of neurotrophin signaling through the p75 neurotrophin receptor. Cell Rep. 2012, 2:1563-1570.
15. Conforti P., Mas Monteys A., Zuccato C., Buckley N.J., Davidson B., Cattaneo E. In vivo delivery of DN:REST improves transcriptional changes of REST-regulated genes in HD mice. Gene Ther. 2013, 20:678-685.
16. Crook Z.R., Housman D. Huntington's disease: can mice lead the way to treatment?. Neuron 2011, 69:423-435.
17. Deinhardt K., Kim T., Spellman D.S., Mains R.E., Eipper B.A., Neubert T.A., Chao M.V., Hempstead B.L. Neuronal growth cone retraction relies on proneurotrophin receptor signaling through Rac. Sci. Signal. 2011, 4:ra82.
18. Du Y., Fischer T.Z., Clinton-Luke P., Lercher L.D., Dreyfus C.F. Distinct effects of p75 in mediating actions of neurotrophins on basal forebrain oligodendrocytes. Mol. Cell. Neurosci. 2006, 31:366-375.
19. Eide F.F., Vining E.R., Eide B.L., Zang K., Wang X.Y., Reichardt L.F. Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J. Neurosci. 1996, 16:3123-3129.
20. Ferrer I., Goutan E., Marin C., Rey M.J., Ribalta T. Brain-derived neurotrophic factor in Huntington disease. Brain Res. 2000, 866:257-261.
21. Gauthier L.R., Charrin B.C., Borrell-Pages M., Dompierre J.P., Rangone H., Cordelieres F.P., De Mey J., MacDonald M.E., Lessmann V., Humbert S., Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118:127-138.
22. Gharami K., Xie Y., An J.J., Tonegawa S., Xu B. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J. Neurochem. 2008, 105:369-379.
23. Giampa C., Montagna E., Dato C., Melone M.A., Bernardi G., Fusco F.R. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease. PLoS ONE 2013, 8.
24. Gines S., Seong I.S., Fossale E., Ivanova E., Trettel F., Gusella J.F., Wheeler V.C., Persichetti F., MacDonald M.E. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum. Mol. Genet. 2003, 12:497-508.
25. HDCRG A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's disease collaborative research group. Cell 1993, 72:971-983.
26. Heikkinen T., Lehtimaki K., Vartiainen N., Puolivali J., Hendricks S.J., Glaser J.R., Bradaia A., Wadel K., Touller C., Kontkanen O., Yrjanheikki J.M., Buisson B., Howland D., Beaumont V., Munoz-Sanjuan I., Park L.C. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. PLoS ONE 2012, 7.
27. Jin J., Peng Q., Hou Z., Jiang M., Wang X., Langseth A.J., Tao M., Barker P.B., Mori S., Bergles D.E., Ross C.A., Detloff P.J., Zhang J., Duan W. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 2015, 24:2508-2527.
28. Kang S.H., Li Y., Fukaya M., Lorenzini I., Cleveland D.W., Ostrow L.W., Rothstein J.D., Bergles D.E. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 2013, 16:571-579.
29. Kells A.P., Fong D.M., Dragunow M., During M.J., Young D., Connor B. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol. Ther. 2004, 9:682-688.
30. Kells A.P., Henry R.A., Connor B. AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment. Gene Ther. 2008, 15:966-977.
31. Liot G., Zala D., Pla P., Mottet G., Piel M., Saudou F. Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J. Neurosci. 2013, 33:6298-6309.
32. Menalled L.B. Knock-in mouse models of Huntington's disease. NeuroRx 2005, 2:465-470.
33. Menalled L.B., Kudwa A.E., Miller S., Fitzpatrick J., Watson-Johnson J., Keating N., Ruiz M., Mushlin R., Alosio W., McConnell K., Connor D., Murphy C., Oakeshott S., Kwan M., Beltran J., Ghavami A., Brunner D., Park L.C., Ramboz S., Howland D. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. PLoS ONE 2012, 7.
34. Mi S., Lee X., Shao Z., Thill G., Ji B., Relton J., Levesque M., Allaire N., Perrin S., Sands B., Crowell T., Cate R.L., McCoy J.M., Pepinsky R.B. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat. Neurosci. 2004, 7:221-228.
35. Mi S., Miller R.H., Lee X., Scott M.L., Shulag-Morskaya S., Shao Z., Chang J., Thill G., Levesque M., Zhang M., Hession C., Sah D., Trapp B., He Z., Jung V., McCoy J.M., Pepinsky R.B. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat. Neurosci. 2005, 8:745-751.
36. Milner T.A., Waters E.M., Robinson D.C., Pierce J.P. Degenerating processes identified by electron microscopic immunocytochemical methods. Methods Mol. Biol. 2011, 793:23-59.
37. Petratos S., Gonzales M.F., Azari M.F., Marriott M., Minichiello R.A., Shipham K.A., Profyris C., Nicolaou A., Boyle K., Cheema S.S., Kilpatrick T.J. Expression of the low-affinity neurotrophin receptor, p75(NTR), is upregulated by oligodendroglial progenitors adjacent to the subventricular zone in response to demyelination. Glia 2004, 48:64-75.
38. Plotkin J.L., Day M., Peterson J.D., Xie Z., Kress G.J., Rafalovich I., Kondapalli J., Gertler T.S., Flajolet M., Greengard P., Stavarache M., Kaplitt M.G., Rosinski J., Chan C.S., Surmeier D.J. Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease. Neuron 2014, 83:178-188.
39. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
40. Seo H., Kim W., Isacson O. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. Hum. Mol. Genet. 2008, 17:3144-3153.
41. Shoulson I., Chase T.N. Huntington's disease. Annu. Rev. Med. 1975, 26:419-436.
42. Simmons D.A., Belichenko N.P., Yang T., Condon C., Monbureau M., Shamloo M., Jing D., Massa S.M., Longo F.M. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease. J. Neurosci. 2013, 33:18712-18727.
43. Smith G.A., Rocha E.M., McLean J.R., Hayes M.A., Izen S.C., Isacson O., Hallett P.J. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease. Hum. Mol. Genet. 2014, 23:4510-4527.
44. Sontag E.M., Lotz G.P., Agrawal N., Tran A., Aron R., Yang G., Necula M., Lau A., Finkbeiner S., Glabe C., Marsh J.L., Muchowski P.J., Thompson L.M. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. J. Neurosci. 2012, 32:11109-11119.
45. Strand A.D., Baquet Z.C., Aragaki A.K., Holmans P., Yang L., Cleren C., Beal M.F., Jones L., Kooperberg C., Olson J.M., Jones K.R. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J. Neurosci. 2007, 27:11758-11768.
46. Takamura A., Sato Y., Watabe D., Okamoto Y., Nakata T., Kawarabayashi T., Oddo S., Laferla F.M., Shoji M., Matsubara E. Sortilin is required for toxic action of Abeta oligomers (AbetaOs): extracellular AbetaOs trigger apoptosis, and intraneuronal AbetaOs impair degradation pathways. Life Sci. 2012, 91:1177-1186.
47. Teng H.K., Teng K.K., Lee R., Wright S., Tevar S., Almeida R.D., Kermani P., Torkin R., Chen Z.Y., Lee F.S., Kraemer R.T., Nykjaer A., Hempstead B.L. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J. Neurosci. 2005, 25:5455-5463.
48. Tomita K., Kubo T., Matsuda K., Fujiwara T., Yano K., Winograd J.M., Tohyama M., Hosokawa K. The neurotrophin receptor p75NTR in Schwann cells is implicated in remyelination and motor recovery after peripheral nerve injury. Glia 2007, 55:1199-1208.
49. Tong X., Ao Y., Faas G.C., Nwaobi S.E., Xu J., Haustein M.D., Anderson M.A., Mody I., Olsen M.L., Sofroniew M.V., Khakh B.S. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. Nat. Neurosci. 2014, 17:694-703.
50. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.
51. Wang K.C., Kim J.A., Sivasankaran R., Segal R., He Z. P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 2002, 420:74-78.
52. Woo N.H., Teng H.K., Siao C.J., Chiaruttini C., Pang P.T., Milner T.A., Hempstead B.L., Lu B. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat. Neurosci. 2005, 8:1069-1077.
53. Xiang Z., Valenza M., Cui L., Leoni V., Jeong H.K., Brilli E., Zhang J., Peng Q., Duan W., Reeves S.A., Cattaneo E., Krainc D. Peroxisome-proliferator-activated receptor gamma coactivator 1 alpha contributes to dysmyelination in experimental models of Huntington's disease. J. Neurosci. 2011, 31:9544-9553.
54. Xie Y., Hayden M.R., Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J. Neurosci. 2010, 30:14708-14718.
55. Yang J., Siao C.J., Nagappan G., Marinic T., Jing D., McGrath K., Chen Z.Y., Mark W., Tessarollo L., Lee F.S., Lu B., Hempstead B.L. Neuronal release of proBDNF. Nat. Neurosci. 2009, 12:113-115.
56. Yang J., Harte-Hargrove L.C., Siao C.J., Marinic T., Clarke R., Ma Q., Jing D., Lafrancois J.J., Bath K.G., Mark W., Ballon D., Lee F.S., Scharfman H.E., Hempstead B.L. proBDNF negatively regulates neuronal remodeling, synaptic transmission, and synaptic plasticity in hippocampus. Cell Rep. 2014, 7:796-806.
57. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., Timmusk T., Sipione S., Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
58. Zuccato C., Tartari M., Crotti A., Goffredo D., Valenza M., Conti L., Cataudella T., Leavitt B.R., Hayden M.R., Timmusk T., Rigamonti D., Cattaneo E. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 2003, 35:76-83.
59. Zuccato C., Liber D., Ramos C., Tarditi A., Rigamonti D., Tartari M., Valenza M., Cattaneo E. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res. 2005, 52:133-139.
60. Zuccato C., Marullo M., Conforti P., MacDonald M.E., Tartari M., Cattaneo E. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol. 2008, 18:225-238.